Andrea Gonzalez, MD
Infectious Disease · Midlothian, VANPI 1336176403
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,500 of the $17,071 with a category attached, or 73.2%. Chromacode, Inc accounts for 73.2% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2023 at $13,205 and has fallen 99.4% since, to $74 in 2025. Among infectious disease clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $81.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chromacode, Inc$13K
- Viiv Healthcare Company$2K
- Merck$527
- Gilead$477
- Insmed, Inc.$280
- Melinta Therapeutics, LLC$204
- plus $1K from 18 others
What the payments were for
- Consulting fees$12,50073%
- Food & beverage$4,53627%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chromacode, Inc | 2 | $12,500 |
| Viiv Healthcare Company | 66 | $1,606 |
| Merck | 28 | $527 |
| Gilead | 17 | $477 |
| Insmed, Inc. | 11 | $280 |
| Melinta Therapeutics, LLC | 11 | $204 |
| AbbVie(2 entities) | 11 | $193 |
| Johnson & Johnson | 12 | $193 |
| La Jolla Pharmaceutical Company | 9 | $168 |
| Theratechnologies Inc. | 6 | $142 |
| Astellas Pharma US Inc | 6 | $139 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $126 |
| Shionogi Inc | 4 | $104 |
| Paratek Pharmaceuticals, Inc. | 6 | $99 |
| Pfizer | 4 | $75 |
| Aurinia Pharma U.S., Inc. | 2 | $42 |
| Pharming Healthcare, Inc. | 2 | $41 |
| Hospira, Inc. | 2 | $38 |
| Octapharma USA, Inc. | 2 | $37 |
| GSK | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Abiomed | 1 | $16 |
| VBI Vaccine (delaware) Inc. | 1 | $13 |
| Abbott | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,071 in reported general payments places this provider in the 90th percentile of 194 infectious disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 231 | $919,637 |
| JulucaDolutegravir/Rilpivirine | 56 | $206,049 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 53 | $204,185 |
| TivicayDolutegravir Sodium | 61 | $188,566 |
| DovatoDolutegravir Sodium/Lamivudine | 32 | $118,837 |
| RukobiaFostemsavir Tromethamine | 11 | $109,554 |
| DescovyEmtricitabine/Tenofov Alafenam | 38 | $102,268 |
| CabenuvaCabotegravir/Rilpivirine | 12 | $89,289 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 19 | $71,079 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 17 | $68,680 |
| IsentressRaltegravir Potassium | 30 | $61,955 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $56,617 |
| PrezcobixDarunavir/Cobicistat | 13 | $30,022 |
| IntelenceEtravirine | 11 | $17,415 |
| Daptomycin | 31 | $17,115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $477 | $1,090,585286 claims |
| Viiv Healthcare CompanyJuluca, Triumeq, Tivicay, Dovato, Rukobia | $1,606 | $916,480225 claims |
| MerckIsentress | $527 | $61,95530 claims |
| Johnson & JohnsonPrezcobix | $193 | $30,02213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 194 infectious disease providers in Virginia.
Other infectious disease in Midlothian
- Mark GentzMidlothian$7K
- Sarika TripathiMidlothian$1K
- Christopher BettacchiMarion$243K
- Stephen WeinrothFairfax$157K
- William PetriCharlottesville$92K
- Michael IsonFalls Church$88K
- Valerie RiddleBumpass$83K
- Edward OldfieldNorfolk$81K
- William FurlongArlington$68K
- Frederick HaydenCharlottesville$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.